Bio Path Holdings Net Income
| BPTH Stock | USD 0.06 0 3.33% |
As of the 10th of February, Bio Path shows the insignificant Risk Adjusted Performance, standard deviation of 10.02, and Mean Deviation of 5.95. Bio Path Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Bio Path Holdings, which can be compared to its peers.
Bio Path's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bio Path's valuation are provided below:Bio Path Holdings does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Bio |
Bio Path 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bio Path's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bio Path.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Bio Path on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Bio Path Holdings or generate 0.0% return on investment in Bio Path over 90 days. Bio Path is related to or competes with Orgenesis, and Helix BioMedix. Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug developmen... More
Bio Path Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bio Path's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bio Path Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 50.79 | |||
| Value At Risk | (16.67) | |||
| Potential Upside | 16.67 |
Bio Path Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Path's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bio Path's standard deviation. In reality, there are many statistical measures that can use Bio Path historical prices to predict the future Bio Path's volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | (0.06) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bio Path's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bio Path February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 5.95 | |||
| Coefficient Of Variation | (5,888) | |||
| Standard Deviation | 10.02 | |||
| Variance | 100.37 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 50.79 | |||
| Value At Risk | (16.67) | |||
| Potential Upside | 16.67 | |||
| Skewness | 0.2876 | |||
| Kurtosis | 0.7985 |
Bio Path Holdings Backtested Returns
Bio Path Holdings secures Sharpe Ratio (or Efficiency) of -0.0178, which signifies that the company had a -0.0178 % return per unit of risk over the last 3 months. Bio Path Holdings exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Bio Path's Standard Deviation of 10.02, mean deviation of 5.95, and insignificant Risk Adjusted Performance to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.06, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Path will likely underperform. At this point, Bio Path Holdings has a negative expected return of -0.19%. Please make sure to confirm Bio Path's information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Bio Path Holdings performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.44 |
Average predictability
Bio Path Holdings has average predictability. Overlapping area represents the amount of predictability between Bio Path time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bio Path Holdings price movement. The serial correlation of 0.44 indicates that just about 44.0% of current Bio Path price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | -0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bio Path Holdings reported net income of (16.08 Million). This is 104.71% lower than that of the Biotechnology sector and 122.95% lower than that of the Health Care industry. The net income for all United States stocks is 102.82% higher than that of the company.
Bio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Path's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics of similar companies.Bio Path is currently under evaluation in net income category among its peers.
Bio Fundamentals
| Return On Equity | -11.6 | |||
| Return On Asset | -1.94 | |||
| Current Valuation | 531.06 K | |||
| Shares Outstanding | 5.77 M | |||
| Shares Owned By Institutions | 7.41 % | |||
| Number Of Shares Shorted | 79.35 K | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 2.33 X | |||
| EBITDA | (15.76 M) | |||
| Net Income | (16.08 M) | |||
| Cash And Equivalents | 17.02 M | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 113 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 15.57 X | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (11.54 M) | |||
| Short Ratio | 0.43 X | |||
| Earnings Per Share | (8.34) X | |||
| Target Price | 12.0 | |||
| Number Of Employees | 10 | |||
| Beta | 0.05 | |||
| Market Capitalization | 1.21 M | |||
| Total Asset | 3.22 M | |||
| Retained Earnings | (107.61 M) | |||
| Working Capital | 1.14 M | |||
| Current Asset | 9.59 M | |||
| Current Liabilities | 937 K | |||
| Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Bio OTC Stock
Bio Path financial ratios help investors to determine whether Bio OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Path security.